Vertex Pharmaceuticals (VRTX) Cost of Revenue (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Cost of Revenue of $392.8 million for Q1 2026, up 8.21% year-over-year from $363.0 million in Q1 2025, and down 15.71% quarter-over-quarter from $466.0 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Cost of Revenue (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Cost of Revenue history runs 18 years deep, the most recent figure standing at $392.8 million for Q1 2026.
- In Q1 2026, Cost of Revenue rose 8.21% year-over-year to $392.8 million; the TTM figure through Mar 2026 stood at $1.7 billion (up 8.4% YoY), while the FY2025 annual figure was $1.7 billion, up 7.89% from the prior year.
- Cost of Revenue for Q1 2026 stood at $392.8 million, down from $466.0 million in the prior quarter.
- The five-year high for Cost of Revenue was $466.0 million in Q4 2025, with the low at $245.8 million in Q1 2022.
- The 5-year median for Cost of Revenue is $363.0 million (2025), against an average of $348.1 million.
- The sharpest annual moves came in 2023 and 2025: Cost of Revenue grew 29.9% in 2023, then gained 5.65% in 2025.
- Vertex Pharmaceuticals' Cost of Revenue stood at $283.3 million in 2022, then advanced by 29.9% to $368.0 million in 2023, then climbed by 15.05% to $423.4 million in 2024, then rose by 10.06% to $466.0 million in 2025, then retreated by 15.71% to $392.8 million in 2026.
- Business Quant data shows VRTX's Cost of Revenue at $392.8 million in Q1 2026, $466.0 million in Q4 2025, and $414.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 489.20 Mn |
| Jun 30, 2026 | 489.20 Mn |
| Mar 31, 2026 | 392.80 Mn |
| Mar 31, 2026 | 392.80 Mn |
| Dec 31, 2025 | 466.00 Mn |
| Dec 31, 2025 | 466.00 Mn |
| Sep 30, 2025 | 414.80 Mn |
| Sep 30, 2025 | 414.80 Mn |
| Jun 30, 2025 | 407.50 Mn |
| Jun 30, 2025 | 407.50 Mn |
| Mar 31, 2025 | 363.00 Mn |
| Mar 31, 2025 | 363.00 Mn |
| Dec 31, 2024 | 423.40 Mn |
| Dec 31, 2024 | 423.40 Mn |
| Sep 30, 2024 | 392.60 Mn |
| Sep 30, 2024 | 392.60 Mn |
| Jun 30, 2024 | 371.90 Mn |
| Jun 30, 2024 | 371.90 Mn |
| Mar 31, 2024 | 342.60 Mn |
| Mar 31, 2024 | 342.60 Mn |